MONTVALE, N.J., Nov. 12 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. today announced the appointment of Paul Blake to the Company’s Board of Directors effective November 9, 2007. Dr. Blake has over 27 years of clinical development experience. He currently serves as the Senior Vice President and Chief Medical Officer of AEterna Zentaris Inc., a bio-pharmaceutical company. Previously, Dr. Blake was Senior Vice President, Clinical Research and Development for Avigenics Inc. From 2001 to 2006, Dr. Blake was with Cephalon, Inc. in the clinical research and regulatory affairs group, most recently as Executive Vice President, Worldwide Medical and Regulatory Operations. He has also served as Chief Medical Officer for MDS Proteomics, Inc. and as Medical Director for SmithKline Beecham Pharmaceuticals, where he was responsible for its worldwide clinical research and development operations.
“We are delighted to welcome Paul to the Board of Directors of Memory Pharmaceuticals,” said Jonathan Fleming, Co-founder of Memory Pharmaceuticals and Chairman of the Company’s Board of Directors. “Paul brings to Memory’s Board a wealth of experience leading the clinical development of early and late-stage drug candidates, across a range of therapeutic areas. We believe his expertise will be of tremendous value as our pipeline matures and our compounds advance through the clinical trial process.”
“I am excited to be joining the Memory Pharmaceuticals Board,” stated Dr. Blake. “The Company has a robust and diverse portfolio of compounds in development for the treatment of debilitating central nervous system disorders, and I look forward to working with the Company and, in particular, the clinical development team as they move current programs into new indications and later stage trials and take new programs into the clinic.”
Dr. Blake received his M.B. and B.S. at London University and is a fellow of the American College of Clinical Pharmacology and the Royal College of Physicians in the United Kingdom.
About the Company
Memory Pharmaceuticals Corp., a biopharmaceutical company, is focused on developing innovative drugs for the treatment of debilitating CNS disorders such as Alzheimer’s disease, schizophrenia and depression. For additional information, please visit our website at http://www.memorypharma.com.
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties. All statements, other than statements of historical facts, regarding management’s expectations, beliefs, goals, plans or Memory Pharmaceuticals’ prospects, future financial position, future revenues and projected costs should be considered forward-looking. Readers are cautioned that actual results may differ materially from projections or estimates due to a variety of important factors, including the risks and uncertainties associated with: obtaining additional financing to support Memory Pharmaceuticals’ R&D and clinical activities and operations; the outcome of clinical trials of Memory Pharmaceuticals’ drug candidates and whether they demonstrate these candidates’ safety and effectiveness; obtaining regulatory approvals to conduct clinical trials and to commercialize Memory Pharmaceuticals’ drug candidates; Memory Pharmaceuticals’ ability to enter into and maintain collaborations with third parties for its drug development programs; Memory Pharmaceuticals’ dependence on its collaborations and its license relationship with Bayer; achieving milestones under Memory Pharmaceuticals’ collaborations; Memory Pharmaceuticals’ dependence on preclinical and clinical investigators, preclinical and clinical research organizations, manufacturers and consultants; and protecting the intellectual property developed by or licensed to Memory Pharmaceuticals. These and other risks are described in greater detail in Memory Pharmaceuticals’ filings with the Securities and Exchange Commission. Memory Pharmaceuticals may not actually achieve the goals or plans described in its forward-looking statements, and investors should not place undue reliance on these statements. Memory Pharmaceuticals disclaims any intent or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.
CONTACT: Jzaneen Lalani, General Counsel of Memory Pharmaceuticals Corp.,
+1-201-802-7249, or Laura Perry of Stern Investor Relations, Inc.,
+1-212-362-1200, for Memory Pharmaceuticals Corp.
Web site: http://www.memorypharma.com/
